Review: Multidrug-resistant tuberculosis: Public health challenges

Tropical Medicine and International Health

Volumn 9, Issue 1, 2004, Pages 25-40

  Coker, Richard J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMYCOBACTERIAL AGENT; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PUBLIC HEALTH; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; VIRULENCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COSTS AND COST ANALYSIS; DISEASE OUTBREAKS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PUBLIC HEALTH; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0842287120     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2003.01156.x     Document Type: Review

References (100)

1. Albert H, Trollip AP, Mole RJ, Hatch SJ & Blumberg L (2002) Rapid indication of multidrug-resistant tuberculosis from liquid cultures using FASTPlaqueTB-RIF, a manual phage-based test. International Journal of Tuberculosis and Lung Diseases 6, 523-528.
2. Alland D, Kalkut GE, Moss AR et al. (1994) Transmission of tuberculosis in New York City - an analysis by DNA finger-printing and conventional epidemiologic methods. New England Journal of Medicine 330, 1710-1716.
3. Atun R, Lennox-Chugani N, Drobniewski F, Samyshkin Y & Coker RJ (in press) Capturing health systems complexity: a conceptual framework for development, implementation, evaluation, and monitoring of communicable disease programmes. EJPH.
4. Becerra MC, Freeman J, Bayona J et al. (2000) Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Diseases 4, 108-114.
5. Bifani PJ, Mathema B, Campo M et al. (2001) Molecular identification of streptomycin monoresistant Mycobacterium tuberculosis related to multidrug-resistant W strain. Emerg Inf Dis 7, 842-848.
6. Billington OJ, McHugh TD & Gillespie SH (1999) Physiological cost of rifampicin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 43, 1866-1869.
7. Brundtland GH (2000) Reith Lecture. BBC at http://news/ bbc.co.uk/hi/english/static/events/reith_2000/lecture4.stm, London.
8. Buhl K & Nyboe J (1967) Epidemiological basis of tuberculosis eradication. Changes in mortality of Danish tuberculosis patients since 1925. Bulletin of WHO 37, 907-925.
9. Canetti G, Fox W, Khomenko AG et al. (1969) Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bulletin of WHO 41, 21-43.
10. CDC (1991a) Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. Morbidity and Mortality Weekly Report 40, 585-591.
11. CDC (1991b) Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system - New York, 1991. Morbidity and Mortality Weekly Report 41, 507-509.
12. CDC (1993) Outbreak of multidrug-resistant tuberculosis at a hospital - New York City, 1991. Morbidity and Mortality Weekly Report 42, 433-434.
13. Coghlan A (2001) Ebola with wings. New Scientist Magazine, London, 7th July 2001, pp. 28.
14. Cohn ML & Davis CL (1970) Infectivity and pathogenicity of drug-resistant strains of tubercle bacilli studied by aerogenic infection of guinea pigs. American Review of Respiratory Diseases 102, 97-100.
15. Coker RJ (2000) From Chaos to Coercion: Detention and the Control of Tuberculosis. St. Martin's Press, New York.
16. Coker R (2001) Just coercion? Detention of non-adherent tuberculosis patients. Annals of the New York Academy of Sciences 953, 216-223.
17. Coker R (2002) Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? International Journal of Tuberculosis and Lung Diseases 6, 649-650.
18. Coker R, Dimitrova B, Drobniewski F et al. (2003) Tuberculosis control in Samara Oblast, Russia: institutional and regulatory environment. International Journal of Tuberculosis and Lung Diseases 10, 920-932.
19. Coninx R, Mathieu C, Debacker M et al. (1999) First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 353, 969-973.
20. Coronado VG, Beck-Sague CM, Hutton MD et al. (1993) Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. Journal of Infectious Diseases 168, 1052-1055.
21. Crofton J (1962) The contribution of treatment to the prevention of tuberculosis. Bulletin of the International Union for Tuberculosis 32, 643-653.
22. Crofton J (1987) The prevention and management of drug resistant tuberculosis. Bulletin of the International Union for Tuberculosis 62, 6-11.
23. Crofton J & Van Deun A (2000) Treatment of multidrug-resistant tuberculosis in developing countries. In: Multidrug-resistant Tuberculosis. (eds I Bastian & F Portaels) Kluwer Academic Publishers, Dordrecht.
24. Crofton J, Chaulet P & Maher D (1996) Guidelines on the Management of Drug-resistant Tuberculosis. World Health Organization, Geneva.
25. Danilova I, Stoyunin M, Repina E et al. (1999) Primary multidrug-resistant tuberculosis - Ivanovo Oblast, Russia. Morbidity and Mortality Weekly Report 48, 661-664.
26. De Beenhouwer H, Lhiang Z, Jannes G et al. (1995) Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuberculosis and Lung Diseases 76, 425-430.
27. Dormandy T (1998) The White Death: a History of Tuberculosis. Hambledon press, London.
28. Drobniewski F, Balabanova Y, Ruddy M et al. (2002a) Rifampin and multiple drug resistant tuberculosis in the Russian civilian and prison sectors - dominance of the Beijing strain family. Emerging Infectious Diseases 8, 1320-1326.
29. Drobniewski F, Eltringham I, Graham C, Magee JG, Smith EG & Watt B (2002b) A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 57, 810-816.
30. Dye C, Scheele S, Dolin P, Pathania V & Raviglione M (1999) Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. Journal of the American Medical Association 282, 677-686.
31. Dye C, Williams BG, Espinal MA & Raviglione MC (2002) Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295, 2042-2046.
32. Edlin BR, Tokars JI, Grieco MH et al. (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 326, 1514-1521.
33. Espinal MA, Kim SJ, Suarez PG et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Journal of the American Medical Association 283, 2537-2345.
34. Farmer P & Kim JY (1998) Community based approaches to the control of multidrug resistant tuberculosis: introducing 'DOTS-plus'. British Medical Journal 317, 671-674.
35. Farmer P, Bayona J, Becerra M et al. (1998) The dilemma of MDR - TB in the global era. International Journal of Tuberculosis and Lung Diseases 2, 869-876.
36. Farmer PE, Timperi R, Mitnick C & Kim JY (1999) Responding to outbreaks of MDRTB: Introducing 'DOTS-Plus'. In: Tuberculosis: a Comprehensive International Approach (eds LB Reichman & ES Hershfield), Marcel Dekker Inc., New York.
37. Fischl MA, Daikos GL, Uttamchandani RB et al. (1992) Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Annals of Internal Medicine 117, 184-190.
38. Frieden TR, Fujiwara PI, Washko RM & Hamburg MA (1995) Tuberculosis in New York City - turning the tide. New England Journal of Medicine 333, 229-233.
39. Frieden TR, Sherman LF, Maw KL et al. (1996) A multi-institutional outbreak of highly drug-resistant tuberculosis. Journal of the American Medical Association 276, 1229-1235.
40. Garcia-Garcia ML, Ponce de Leon A, Jimenez-Corona ME et al. (2000) Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Archives of Internal Medicine 160, 630-636.
41. Goble M, Iseman MD & Madsen LA (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. New England Journal of Medicine 328, 527-532.
42. Grimaldo ER, Tupasi TE, Rivera AB et al. (2001) Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. International Journal of Tuberculosis and Lung Diseases 5, 546-550.
43. Grzybowski S (1983) Tuberculosis and its Prevention. Warren H Green, Inc., St Louis, MO.
44. Gupta R, Kim JY, Espinal MA et al. (2001) Public health. Responding to market failures in tuberculosis control. Science 293, 1049-1051.
45. Hadiarto M, Tjandra YA & Hudoyo A (1996) Treatment of multidrug-resistant tuberculosis in Indonesia. Chemotherapy 42(Suppl 3), 24-29.
46. Heifets L & Cangelosi GA (1999) Drug susceptibility testing of Mycobacterium tuberculosis - a neglected problem at the turn of the century. International Journal of Tuberculosis and Lung Diseases 3, 564-581.
47. Kent PT & Kubica GP (eds) (1985) Public Health Mycobacteriology: a Guide for the Level III Laboratory. US Department of Health and Human Services, Atlanta, GA.
48. Kim HJ, Hong YP, Kim SJ, Lew WJ & Lee EG (2001) Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. International Journal of Tuberculosis and Lung Diseases 5, 1129-1136.
49. Kimerling ME, Kluge H, Vezhnina N et al. (1999) Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. International Journal of Tuberculosis and Lung Diseases 3, 451-453.
50. Lan NTN, Lademarco MF, Binkin NJ, Tung LB, Quy HTW & Cj NV (2001) A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. International Journal of Tuberculosis and Lung Diseases 5, 575-578.
51. Lopez B, Aguilar D, Orozco H et al. (2003) A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clinical and Experimental Immunology 133, 30-37.
52. McNerney R, Kiepiela P, Bishop KS, Nye PM & Stoker NG (2000) Rapid screening of Mycobacterium tuberculosis for susceptibility to rifampicin and streptomycin. International Journal of Tuberculosis and Lung Diseases 4, 69-75.
53. Mejia GI, Castrillon I, Trujillo H & Robledo JA (1999) Microcolony detection in TH11 thin layer culture is an alternative for rapid diagnosis of Mycobacterium tuberculosis infection. International Journal of Tuberculosis and Lung Diseases 3, 138-142.
54. Mitchison DA & Nunn AJ (1986) Influence of initial drug resistance on response to short-course chemotherapy of pulmonary tuberculosis. American Review of Respiratory Diseases 133, 423-430.
55. Mitchison DA, Wallace JG, Bhatia AL et al. (1960) A comparison of the virulence in guinea pigs of South India and British tubercle bacilli. Tubercle 41, 1-22.
56. Mitnick C, Bayona J, Palacios E et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of Medicine 348, 119-128.
57. National Tuberculosis Institute (1974) Tuberculosis in a rural population of South India: a five year epidemiological study. Bulletin of WHO 51, 473.
58. Nitta AT, Knowles LS, Kim JY et al. (2002) Limited transmission of multidrug-resistant tuberculosis despite a high proportion of infectious cases in Los Angeles County, California. American Journal of Respiratory Review and Critical Care Medicine 165, 812-817.
59. Open Society Institute (1999) The Global Impact of Drug-resistant Tuberculosis. Harvard Medical School, Open Society Institute, Boston, MA.
60. Pablos-Mendez A, Raviglione MC, Laszlo A et al. (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997. New England Journal of Medicine 338, 1641-1649.
61. Pai S, Esen N, Pan X & Musser JM (1997) Routine rapid Mycobacterium species assignment based on species-specific allelic variation in the 65-kilodalton heat shock protein gene (hsp 65). Archives of Pathology and Laboratory Medicine 121, 859-864.
62. Palomino JC (2000) Novel rapid antimicrobial susceptibility tests for Mycobacterium tuberculosis. In: Multidrug-resistant Tuberculosis (eds I Bastian & F Portaels), Kluwer Academic Publishers, Dordrecht.
63. Park MM, Davis AL, Schluger NW, Cohen H & Rom WN (1996) Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. American Journal of Respiratory and Critical Care Medicine 153, 317-324.
64. Park SK, Kim CT & Song SD (1998) Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. International Journal of Tuberculosis and Lung Diseases 2, 877-884.
65. Pearson ML, Jereb JA, Frieden TR et al. (1992) Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and health workers. Annals of Internal Medicine 117, 191-196.
66. Polivakho VV & Sharaburova OE (2000) The economic aspects of the system of organizing antitubercular measures in Tomsk Province. Problemy Tuberkuleza 5, 32-35.
67. Pretorius GS, Sirgel FA, Schaaf HS, van Helden PD & Victor TC (1996) Rifampicin resistance in Mycobacterium tuberculosis -rapid detection and implications in chemotherapy. South African Medical Journal 86, 50-55.
68. Quy HTW, Lan NTN, Borgdorff MW et al. (2003) Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? International Journal of Tuberculosis and Lung Diseases 7, 631-636.
69. Raviglione M (2000) DOTS and multidrug-resistant tuberculosis. In: Multidrug-resistant Tuberculosis (eds I Bastian & F Portaels), Kluwer Academic Publishers, Dordrecht.
70. Reichman L & Tanne J (2002) Timebomb: the Global Epidemic of Multi-drug Resistant Tuberculosis. MGraw-Hill, New York.
71. Reisner BS, Gatson AM & Woods GL (1995) Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampicin. Diagnostic Microbiology and Infectious Disease 22, 325-329.
72. Roberts G, Goodman NL, Heifets L et al. (1983) Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of M. tuberculosis from acid-fast smear-positive specimens. Journal of Clinical Microbiology 18, 689-696.
73. Rosenkrantz BG (ed.) (1994) From Consumption to Tuberculosis: a Documentary History. Garland Publishing Inc., New York.
74. Rothman SM (1995) Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History. The Johns Hopkins University Press, Baltimore, MD.
75. Schaberg T, Reichert B, Schulin T, Lode H & Mauch H (1995) Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. European Respiratory Journal 8, 1688-1693.
76. Snider DE, Kelly GD, Cauthen GM, Thompson NJ & Kilburn JO (1985) Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. American Review of Respiratory Diseases 132, 125-132.
77. van Soolingen D, Borgdorff MW, de Haas PE et al. (1999) Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. Journal of Infectious Diseases 180, 726-736.
78. Stephens MG (1941) Follow-up of 1,041 tuberculosis patients. American Review of Tuberculosis 44, 451-462.
79. Stern V, editor. (1999) Sentenced to Die? The Problems of TB in Prisons in Eastern Europe and Central Asia. International Centre for Prison Studies, London.
80. Suarez PG, Floyd K, Portacarrero J et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359, 1980-1989.
81. Suo J, Yu MC, Lee CN, Chiang CY & Lin TP (1996) Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy 42(Suppl 3), 20-23.
82. Tahaoglu K, Torun T, Sevim T et al. (2001) The treatment of multidrug-resistant tuberculosis in Turkey. New England Journal of Medicine 345, 170-174.
83. Takiff H & Heiferts L (2002) In search of rapid diagnosis and drug-resistance detection tools is the FASTPlaqueTB test the answer. International Journal of Tuberculosis and Lung Diseases 6, 635-640.
84. Tattersall WH (1947) The survival of sputum-positive consumptives. A study of 1,192 cases in a county borough between 1914 and 1940. Tubercle 28, 85-96.
85. Teixeira L, Perkins MD, Johnson JL et al. (2001) Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Diseases 5, 321-328.
86. Telzak EE, Sepkowitz KA, Alpert P et al. (1995) Multidrug-resistant tuberculosis in patients without HIV infection. New England Journal of Medicine 333, 907-911.
87. Telzak EE, Sepkowitz KA, Medard F et al. (1997) Durable remission after successful treatment of multidrug-resistant tuberculosis among HIV-negative patients. Abstract in 35th Annual Meeting of the Infectious Diseases Society of America, September 13-16, San Francisco, CA, USA.
88. Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I et al. (1995) Improved outcomes for patients with multidrug-resistant tuberculosis. Clinical Infectious Diseases 21, 1238-1244.
89. UNAIDS (2002) Report on the global HIV/AIDS epidemic. UNAIDS, Geneva.
90. Vareldzis BP, Grosset J, de Kantor I et al. (1994) Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. Tubercle and Lung Disease 75, 1-7.
91. Voelker R (1998) Ebola with wings. Journal of the American Medical Association 280, 1216.
92. White VL & Moore-Gillon J (2000) Resource implications of patients with multidrug resistant tuberculosis. Thorax 55, 962-963.
93. WHO (1997a) Treatment of Tuberculosis: Guidelines for National Programmes. World Health Organization, Geneva.
94. WHO (1997b) Global Tuberculosis Programme: Treatment of Tuberculosis - Guidelines for National Programmes, 2nd edn. World Health Organization, Geneva.
95. WHO (2000) Anti-tuberculosis Drug Resistance in the World: Prevalence and Trends, Report no. 2 World Health Organization, Geneva.
96. WHO (2000) Anti-tuberculosis Drug Resistance in the World, 2nd report. World Health Organization, Geneva.
97. Wiliams DL, Spring L, Gillis TP, Salfinger M & Persing DH (1998) Evaluation of a polymerase chain reaction-based universal heteroduplex generator assay for direct detection of rifampicin susceptibility of Mycobacterium tuberculosis from sputum specimens. Clinical Infectious Diseases 26, 446-450.
98. Wolinksky E, Smith MM & Steenken W (1956) Isoniazid susceptibility, catalase activity, and guinea pig virulence of recently isolated cultures of tubercle bacilli. American Review of Tuberculosis 73, 768-772.
99. Yew WW, Chan CK, Chau CH et al. (2000) Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 117, 744-751.
100. Zhang Y, Permar S & Sun Z (2002) Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. Journal of Medical Microbiology 51, 42-49.